Literature DB >> 35288863

Risk of Cancer in Inflammatory Bowel Disease and Pitfalls in Oncologic Therapy.

Renata D Peixoto1, Artur R Ferreira2, James M Cleary3, João P Fogacci2, João P Vasconcelos2, Alexandre A Jácome2.   

Abstract

BACKGROUND: Inflammatory bowel disease (IBD), represented by ulcerative colitis and Crohn's disease, is an idiopathic condition caused by a dysregulated immune response to host intestinal microflora, leading to chronic relapsing intestinal inflammation. Individuals with IBD are more prone to die from several diseases, including cancer.
METHODS: An extensive search was conducted of PubMed using the following medical subject heading-"inflammatory bowel disease" OR "Crohn's disease" OR "ulcerative colitis" AND "cancer."
RESULTS: In this review article, we discuss the oncogenic mechanisms and genomics of colitis-associated colorectal cancer. Beyond this, we describe the multiple other malignancies that IBD patients are at risk for, discuss caveats in the screening and diagnosis of those cancers, and shed light on pitfalls on the management and treatment of cancer in IBD patients.
CONCLUSION: Patients, caregivers, and health professionals who deal with IBD must be educated on how to identify warning signs so that cancers can be diagnosed and treated as early as possible.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cancer risk; Cancer treatment; Inflammatory bowel disease

Year:  2022        PMID: 35288863     DOI: 10.1007/s12029-022-00816-0

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  68 in total

1.  Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared.

Authors:  Jonathan M Rhodes; Barry J Campbell
Journal:  Trends Mol Med       Date:  2002-01       Impact factor: 11.951

Review 2.  Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?

Authors:  Laurent Beaugerie
Journal:  Gut       Date:  2011-12-09       Impact factor: 23.059

Review 3.  Etiopathogenesis of inflammatory bowel diseases.

Authors:  Silvio Danese; Claudio Fiocchi
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

4.  Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010.

Authors:  Tine Jess; Morten Frisch; Jacob Simonsen
Journal:  Clin Gastroenterol Hepatol       Date:  2012-09-27       Impact factor: 11.382

Review 5.  Inflammation and colon cancer.

Authors:  Janos Terzić; Sergei Grivennikov; Eliad Karin; Michael Karin
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

Review 6.  Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment.

Authors:  Jordan E Axelrad; Simon Lichtiger; Vijay Yajnik
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

Review 7.  Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer.

Authors:  S Danese; A Mantovani
Journal:  Oncogene       Date:  2010-04-19       Impact factor: 9.867

Review 8.  Colorectal Cancer in Inflammatory Bowel Disease.

Authors:  Ryan W Stidham; Peter D R Higgins
Journal:  Clin Colon Rectal Surg       Date:  2018-04-01

Review 9.  Inflammatory bowel disease.

Authors:  Clara Abraham; Judy H Cho
Journal:  N Engl J Med       Date:  2009-11-19       Impact factor: 91.245

View more
  1 in total

Review 1.  Mesenchymal Stem Cell-Derived Secretome: A Potential Therapeutic Option for Autoimmune and Immune-Mediated Inflammatory Diseases.

Authors:  Györgyi Műzes; Ferenc Sipos
Journal:  Cells       Date:  2022-07-26       Impact factor: 7.666

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.